James Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Hall has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Mark J. O'Connor
Oncology Targeted Discovery, AstraZeneca, Cambridge, UK
64 shared publications - Mathew J. Garnett
Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
55 shared publications - Caitlin Hall
Wellcome Sanger Institute, Cambridge, United Kingdom
54 shared publications - Charlotte Tolley
Wellcome Sanger Institute, Cambridge, United Kingdom
54 shared publications - Frances Thomas
School of Natural Sciences, Birkbeck University of London, London, United Kingdom
54 shared publications - James Morris
Wellcome Sanger Institute, Cambridge, UK
54 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 657 (8132) , 765-774
A tumour-derived organoid biobank maps cancer gene dependencies
Cancer cell lines remain foundational for research and drug discovery, yet they incompletely capture tumour diversity, lack linked patient context, and have undergone adaptation to culture. Tumour organoids are three-dimensional cultures derived from patient tissue that offer a powerful complement to cell lines 1 . Here we derived and characterized 256 clinically annotated tumour organoids directly from colorectal, oesophageal, ovarian, pancreatic and gastric cancers as renewable, genetically stable models. Extensive characterization of each model and matched patient tumour samples included whole-genome and transcriptome sequencing, and genome-wide CRISPR–Cas9 screens across 162 organoids mapped gene dependencies. Integrative analyses revealed genomic and clinical markers of dependency across common and rare subtypes, identified organoid-specific essential genes, and revealed targetable vulnerabilities following tumour evolution in paired pre- and post-treatment samples. In colorectal cancer, functional and pharmacological interrogation of the EGFR–RAS–MAPK axis uncovered differential effects of KRAS variant alleles. This open, publicly available resource provides a systematic map of gene dependencies in patient-derived organoids, expanding the model diversity and mechanistic insight needed to advance precision oncology.
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 657 (8132) , 765-774
Top Cited PapersOpen AccessA tumour-derived organoid biobank maps cancer gene dependencies
Cancer cell lines remain foundational for research and drug discovery, yet they incompletely capture tumour diversity, lack linked patient context, and have undergone adaptation to culture. Tumour organoids are three-dimensional cultures derived from patient tissue that offer a powerful complement to cell lines 1 . Here we derived and characterized 256 clinically annotated tumour organoids directly from colorectal, oesophageal, ovarian, pancreatic and gastric cancers as renewable, genetically stable models. Extensive characterization of each model and matched patient tumour samples included whole-genome and transcriptome sequencing, and genome-wide CRISPR–Cas9 screens across 162 organoids mapped gene dependencies. Integrative analyses revealed genomic and clinical markers of dependency across common and rare subtypes, identified organoid-specific essential genes, and revealed targetable vulnerabilities following tumour evolution in paired pre- and post-treatment samples. In colorectal cancer, functional and pharmacological interrogation of the EGFR–RAS–MAPK axis uncovered differential effects of KRAS variant alleles. This open, publicly available resource provides a systematic map of gene dependencies in patient-derived organoids, expanding the model diversity and mechanistic insight needed to advance precision oncology.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 3 shows combination-cancer type pairs with 10 percent or more responder cell lines
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 3 shows combination-cancer type pairs with 10 percent or more responder cell lines
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Dose response matrix combination screening landscape. A, Schematic of screen and analysis. Created with BioRender.com. B, Overview of cell line cancer types. C, Drug combinations screened grouped by drug target pathways. D, Combo Emax for 755 cell lines screened with 109 combinations. White represents combination/cell line pairs not screened.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Dose response matrix combination screening landscape. A, Schematic of screen and analysis. Created with BioRender.com. B, Overview of cell line cancer types. C, Drug combinations screened grouped by drug target pathways. D, Combo Emax for 755 cell lines screened with 109 combinations. White represents combination/cell line pairs not screened.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Combination activity of selumetinib plus venetoclax or AZD5991 in AML. A and B, Combo Emax versus HSA scores in 19 AML cell lines exposed to selumetinib combined with (a) venetoclax or (b) AZD5991. C and D, NOMO1 growth inhibition and HSA excess to the combination of selumetinib with (c) venetoclax or (d) AZD5991. E and F, Western blot analysis for apoptosis markers in NOMO1 cells following time course treatment with selumetinib (300 nmol/L) combined with (e) venetoclax (300 nmol/L) or (f) AZD5991 (100 nmol/L). G, Tumor growth in NOMO1 xenografts treated with selumetinib, AZD5991, or venetoclax alone or in combination for 28 days (n = 5 each arm). Control and monotherapy experimental arms were halted once the maximum permitted tumor volume (2,000 cm3) was reached. Data are plotted as mean tumor volume ± SEM.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Combination activity of selumetinib plus venetoclax or AZD5991 in AML. A and B, Combo Emax versus HSA scores in 19 AML cell lines exposed to selumetinib combined with (a) venetoclax or (b) AZD5991. C and D, NOMO1 growth inhibition and HSA excess to the combination of selumetinib with (c) venetoclax or (d) AZD5991. E and F, Western blot analysis for apoptosis markers in NOMO1 cells following time course treatment with selumetinib (300 nmol/L) combined with (e) venetoclax (300 nmol/L) or (f) AZD5991 (100 nmol/L). G, Tumor growth in NOMO1 xenografts treated with selumetinib, AZD5991, or venetoclax alone or in combination for 28 days (n = 5 each arm). Control and monotherapy experimental arms were halted once the maximum permitted tumor volume (2,000 cm3) was reached. Data are plotted as mean tumor volume ± SEM.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S11 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 11 lists combination drug categories
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 11 lists combination drug categories
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 18 shows drug response data for single agents and combination treatments
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 18 shows drug response data for single agents and combination treatments
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Shortlisting for active and selective combinations. A, Growth inhibition (Emax) and HSA matrix plots were generated for each combination in every cell line. Combo Emax and HSA were used to identify active combinations with benefit over single agent. B, Combinations were filtered on the basis of their activity and selectivity in the tested cancer types. C, Activity of each combination tested in this screen in 41 cancer types. The fraction of cell lines where the combinations are active is indicated and combinations are grouped by category. D and E, Top 10 hits in hematologic cancers (D) and solid tumors (E). Percentage of responder cell lines for each combination in each cancer type plotted versus cancer-type specificity scores. Each color represents a cancer type and combination categories are represented by different shapes. CD, cell death; DDR, DNA damage response; CS, cell signaling; chemo, chemotherapeutic agents.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Shortlisting for active and selective combinations. A, Growth inhibition (Emax) and HSA matrix plots were generated for each combination in every cell line. Combo Emax and HSA were used to identify active combinations with benefit over single agent. B, Combinations were filtered on the basis of their activity and selectivity in the tested cancer types. C, Activity of each combination tested in this screen in 41 cancer types. The fraction of cell lines where the combinations are active is indicated and combinations are grouped by category. D and E, Top 10 hits in hematologic cancers (D) and solid tumors (E). Percentage of responder cell lines for each combination in each cancer type plotted versus cancer-type specificity scores. Each color represents a cancer type and combination categories are represented by different shapes. CD, cell death; DDR, DNA damage response; CS, cell signaling; chemo, chemotherapeutic agents.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S10 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 10 shows the number of hits using different % response scoring thresholds
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 10 shows the number of hits using different % response scoring thresholds
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 2 lists drugs and drug combinations used
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 2 lists drugs and drug combinations used
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S7 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 7 shows the top combination-cancer type pairs in hematological cancers showing activity in at least 10% of tested cell lines in that specific cancer type ranked based on their activity (% responders) and disease selectivity
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Supplementary Table 7 shows the top combination-cancer type pairs in hematological cancers showing activity in at least 10% of tested cell lines in that specific cancer type ranked based on their activity (% responders) and disease selectivity